Zeltia Group's Success May Energize Spanish Biotechs

BILBAO, Spain – The coming months will be a crucial period in the development of Zeltia Group, Spain's flagship biotechnology company, which is due to report data from several clinical trials, including a Phase IIb trial of Nypta (tideglusib) in Alzheimer's disease and a Phase III trial of Aplidin (ptilidepsin) in multiple myeloma.

Given Madrid-based Zeltia's overwhelming prominence within the country's otherwise immature sector, success in either indication would represent a major confidence boost for an industry that is facing stiff headwinds.